In Segment C, contributors will receive ABBV-744 and oral navitoclax. In Phase D, participants will acquire ABBV-744 and ruxolitinib. Contributors will receive treatment right until illness progression or even the individuals are not able to tolerate the study drugs. In general, our recent work highlights the potential utilization of ARV-825 https://jimir898dpa1.topbloghub.com/profile